24 completed, 12 unknown, 1 recruiting. 19 Phase 4, 9 Phase 3, 5 Phase 2, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 19 | Completed 12, Unknown 7 |
| Phase 3 | 9 | Completed 8, Unknown 1 |
| Phase 2 | 5 | Completed 3, Unknown 2 |
| Early Phase 1 | 2 | Unknown 2 |
Follow CoronaVac: new trials by email Literature Review of CoronaVac trials Research Report on CoronaVac
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People CoronaVac, SCTV01E - COVID-19 SARS-CoV-2 Infection | Phase 3 | Unknown | Sinocelltech Ltd. | 6000 | 2023-01-25 | 2023-01-13 |
| Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351 V-01D-351, CoronaVac - COVID-19 Pandemic | Early Phase 1 | Unknown | Livzon Pharmaceutical Group Inc. | 40 | 2022-08-15 | 2022-10-19 |
| Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant), COVID-19 Vaccine (Vero cell), Inactivated (CZ strain) - COVID-19 | Phase 3 | Completed | Sinovac Research and Development Co., Ltd. | 1750 | 2022-06-01 | 2024-05-31 |
| The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001 LYB001, CoronaVac - COVID-19, Vaccine Reaction | Early Phase 1 | Unknown | Guangzhou Patronus Biotech Co., Ltd. | 120 | 2022-05-14 | 2023-07-03 |
| Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine Ad5-nCoV-IH, Ad5-nCoV-IM, CoronaVac - COVID-19 | Phase 4 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 362 | 2022-04-23 | 2025-02-21 |
| Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine Inactivated COVID-19 Vaccine - COVID-19 | Phase 4 | Unknown | Sinovac Life Sciences Co., Ltd. | 180 | 2022-04-19 | 2023-11-07 |
| Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent TURKOVAC, CoronaVac - COVID-19, Sars-CoV-2 Infection | Phase 2 | Completed | Health Institutes of Turkey | 1 | 2022-02-18 | 2024-05-28 |
| Immunogenicity of an Inactivated COVID-19 Vaccine Inactivated COVID-19 Vaccine - COVID-19 | Phase 4 | Completed | Sinovac Research and Development Co., Ltd. | 395 | 2022-01-08 | 2023-09-25 |
| Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19 High-dosage SARS-CoV-2 vaccine, Medium-dosage SARS-CoV-2 vaccine - COVID-19 | Phase 4 | Unknown | Sinovac Biotech Co., Ltd | 1200 | 2021-12-17 | 2022-03-02 |
| Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years COVID-19 Vaccine,Inactivated - COVID-19 | Phase 3 | Completed | Sinovac Research and Development Co., Ltd. | 1000 | 2021-11-27 | 2023-10-16 |
| Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study) BNT162b2, CoronaVac - COVID-19 Vaccination | Phase 4 | Completed | The University of Hong Kong | 451 | 2021-11-18 | 2026-05-15 |
| Phase 3 Booster Vaccination Against COVID-19 CoronaVac, Turkovac - COVID-19, Sars-CoV-2 Infection | Phase 3 | Completed | Health Institutes of Turkey | 4340 | 2021-10-08 | 2024-02-29 |
| Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents Inactivated COVID-19 Vaccine, Controlled vaccine - COVID-19 | Phase 3 | Completed | Sinovac Research and Development Co., Ltd. | 11349 | 2021-09-10 | 2023-10-16 |
| Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults Recombinant SARS-CoV-2 Ad5 vectored vaccine, Inactive SARS-CoV-2 vaccine (Vero cell) - COVID-19 | Phase 4 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 300 | 2021-08-26 | 2022-08-16 |
| Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic Inactivated COVID-19 Vaccine - COVID-19 | Completed | Sinovac Research and Development Co., Ltd. | 1400 | 2021-08-17 | 2022-08-23 | |
| Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2 - COVID-19 | Phase 4 | Unknown | Sinovac Research and Development Co., Ltd. | 2520 | 2021-07-27 | 2023-11-07 |
| Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents Experimental Group - COVID-19 | Phase 4 | Completed | Sinovac Life Sciences Co., Ltd. | 31041 | 2021-07-24 | 2023-09-25 |
| Booster Vaccination Against COVID-19 CoronaVac, Turkovac - COVID-19, Sars-CoV-2 Infection | Phase 2 | Completed | Health Institutes of Turkey | 222 | 2021-07-12 | 2023-11-29 |
| Immunogenicity and Safety of an Inactivated COVID-19 Vaccine Inactivated COVID-19 Vaccine, 23-valent pneumococcal polysaccharide vaccine, Inactivated Hepatitis A Vaccine - COVID-19 | Phase 4 | Completed | Sinovac Research and Development Co., Ltd. | 270 | 2021-07-09 | 2022-04-14 |
| Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster Placebo, Inactivated vaccine booster, mRNA vaccine booster - Covid19 | Phase 2 | Unknown | Universidad del Desarrollo | 534 | 2021-07-08 | 2021-08-05 |
Showing 20 of 37. Sign in to see all of them.
COVID-19 (33) · Acquired Immunodeficiency Syndrome (1) · Arthritis, Rheumatoid (1) · Coronavirus Infections (1) · HIV Infections (1) · Lupus Erythematosus, Systemic (1) · Rheumatic Diseases (1) · Severe Acute Respiratory Syndrome (1)
Sinovac Research and Development Co., Ltd. (10) · Health Institutes of Turkey (5) · Jiangsu Province Centers for Disease Control and Prevention (3) · Sinovac Life Sciences Co., Ltd. (3) · Butantan Institute (2) · The University of Hong Kong (2) · D'Or Institute for Research and Education (1) · Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (1) · Guangzhou Patronus Biotech Co., Ltd. (1) · Hospital do Rim e Hipertensão (1) · Humanity & Health Medical Group Limited (1) · Livzon Pharmaceutical Group Inc. (1) · Masaryk University (1) · Pontificia Universidad Catolica de Chile (1) · Sinocelltech Ltd. (1)
China (18) · Brazil (6) · Turkey (Türkiye) (5) · Chile (3) · Hong Kong (2) · Canada (1) · Croatia (1) · Czechia (1) · Dominican Republic (1) · Estonia (1) · Ethiopia (1) · Germany (1) · Ghana (1) · Malaysia (1) · Mexico (1)
Hongxing Pan, Master (4) · Dongjuan Zhang (2) · Fubing Wang (2) · Jing-Xin Li, PhD (2) · Li Zhang, Master (2) · Qing Wang (2) · Qiuyun Deng (2) · Ruizhi Zhang (2) · Shicheng Guo (2) · Xiaoqiang Liu, Doctor (2) · Xiaoshu Zhang (2) · Xing Fang (2) · Yeqing Tong (2) · Zhaodan Sun (2) · Ahmet Omma, Assoc. Prof. (1)
PMID 35464483, PMID 36658045, PMID 33849629, PMID 34246358, PMID 34292214, PMID 34331051, PMID 34360156, PMID 34659237, PMID 34664616, PMID 34806342, PMID 34882589, PMID 34894235, PMID 34901885, PMID 34954325, PMID 34974453, PMID 35087233, PMID 35135832, PMID 35193873, PMID 35277389, PMID 35306594, PMID 35441164, PMID 35639644, PMID 35764637, PMID 35844042, PMID 36150668, PMID 36192386, PMID 36226829, PMID 36315843, PMID 36383021, PMID 36441137, PMID 36529052, PMID 36870351, PMID 36898400, PMID 37202147, PMID 37291679, PMID 37325662, PMID 37360864, PMID 37549680, PMID 38812507, PMID 39107270, PMID 39191745, PMID 41714650, PMID 42261247, PMID 42329996, PMID 42464341